Article

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study

2015-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: df70faec-979f-5747-9663-5a627e2a6daf
DOI: 10.1186/2051-1426-3-s2-p168
PMCID: PMC4645562

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation studyDOI 10.1186/2051-1426-3-s2-p168Read

Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesSemantic proximity Read

Engineered T cells for cancer therapySemantic proximity Read

Engineering Melanoma Progression in a Humanized Environment In VivoSemantic proximity Read

Engineered T cells for anti-cancer therapySemantic proximity Read

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Semantic proximity Read

Strategies to genetically engineer T cells for cancer immunotherapySemantic proximity Read

T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studiesSemantic proximity Read

Adoptive T-Cell Therapy for Cancer.Semantic proximity Read

Adoptive immunotherapy for cancer: the next generation of gene‐engineered immune cellsSemantic proximity Read

Clinical application of genetically modified T cells in cancer therapySemantic proximity Read

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating LymphocytesSemantic proximity Read

Adoptive cell transfer as personalized immunotherapy for human cancer.Semantic proximity Read